Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024-Reference-Cited by-同舟云学术

Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

Published:2024-02-08 Issue:6 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

López-Lacort Mónica¹²³^ORCID,Muñoz-Quiles Cintia¹²³,Mira-Iglesias Ainara²³,López-Labrador F Xavier⁴⁵²,Mengual-Chuliá Beatriz⁵²,Fernández-García Carlos³,Carballido-Fernández Mario⁶⁷,Pineda-Caplliure Ana⁸,Mollar-Maseres Juan⁹,Shalabi Benavent Maruan¹⁰,Sanz-Herrero Francisco¹¹,Zornoza-Moreno Matilde¹²,Pérez-Martín Jaime Jesús¹²,Alfayate-Miguelez Santiago¹²,Pérez Crespo Rocío¹³,Bastida Sánchez Encarnación¹³,Menasalvas-Ruiz Ana Isabel¹⁴,Téllez-González Mª Cinta¹⁴,Esquiva Soto Samuel¹⁴,Del Toro Saravia Carlos¹⁵,Sanz-Muñoz Iván¹⁶,Eiros José María¹⁶,Matías Del Pozo Vanesa¹⁷,Toquero-Asensi Marina¹⁷,Pastor-Villalba Eliseo¹⁸,Lluch-Rodrigo José Antonio¹⁸,Díez-Domingo Javier¹⁹²³,Orrico-Sánchez Alejandro¹⁹²³

Affiliation:

1. These authors contributed equally to this article and share first authorship.

2. CIBERESP, Instituto de Salud Carlos III, Madrid, Spain

3. Vaccine Research Department, Fisabio-Public Health, Valencia, Spain

4. Department of Microbiology and Ecology, Medical School, University of Valencia, Valencia, Spain

5. Virology Laboratory, Fisabio-Public Health, Valencia, Spain

6. Medicine Department, Universidad CEU Cardenal Herrera, Castellón de la Plana, Spain

7. Hospital General Universitario de Castellón, Castellón, Spain

8. Hospital Universitario Dr. Peset, Valencia, Spain

9. Hospital Universitario La Fe, Valencia, Spain

10. Hospital Marina Baixa, Alicante, Spain

11. Hospital General Universitario, Valencia, Spain

12. Murcia Health Council, Murcia, Spain

13. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

14. Hospital General Universitario Santa Lucía, Murcia, Spain

15. Hospital Rafael Méndez, Murcia, Spain

16. National Influenza Centre, Valladolid, Spain

17. Hospital Clínico, Valladolid, Spain

18. Dirección General de Salud Pública, Valencia, Spain

19. Catholic University of Valencia, Valencia, Spain

Abstract

The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference14 articles.

1. Single-dose nirsevimab for prevention of RSV in preterm infants.;Griffin;N Engl J Med,2020

2. Nirsevimab for prevention of RSV in healthy late-preterm and term infants.;Hammitt;N Engl J Med,2022

3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.;Simões;Lancet Child Adolesc Health,2023

4. Nirsevimab for prevention of hospitalizations due to RSV in infants.;Drysdale;N Engl J Med,2023

5. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.;Ernst;Euro Surveill,2024

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments;Pediatrics;2024-09-11

2. The Need for RSV Prophylaxis in LMICs;Pediatrics;2024-09-10

3. Antiviral agents and therapeutics against respiratory viruses;Expert Opinion on Investigational Drugs;2024-09-08

4. Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes;Infectious Diseases and Therapy;2024-09-05

5. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study;The Lancet Regional Health - Europe;2024-09